Results 31 to 40 of about 57,446 (263)

A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression. [PDF]

Pharmaceuticals (Basel), 2021
Prostate cancer (PCa) is the major cause of cancer-related death in males; however, effective treatments to prevent aggressive progression remain an unmet need.
Sun BL, Tang L, Sun X, Garcia AN, Camp SM, Posadas E, Cress AE, Garcia JGN.   +7 more
europepmc   +2 more sources

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. [PDF]

Neuro Oncol, 2022
BACKGROUND Tumor-specific metabolic processes essential for cell survival are promising targets to potentially circumvent intratumoral heterogeneity, a major resistance factor in gliomas.
Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK.   +9 more
europepmc   +2 more sources

Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer

Journal of Medicinal Chemistry, 2022
Nicotinamide phosphoribosyltransferase (NAMPT) is identified as a promising target for cancer therapy. However, known NAMPT inhibitors are characterized by weak clinical efficacy and dose-dependent toxicity.
Kaijian Bi, Junfei Cheng, Shipeng He, Yuxin Fang, Min Huang, Chunquan Sheng, Guoqiang Dong   +6 more
openalex   +2 more sources

Metabolic Enzyme Triosephosphate Isomerase 1 and Nicotinamide Phosphoribosyltransferase, Two Independent Inflammatory Indicators in Rheumatoid Arthritis: Evidences From Collagen-Induced Arthritis and Clinical Samples. [PDF]

Front Immunol, 2021
Metabolic intervention is a novel anti-rheumatic approach. The glycolytic regulator NAMPT has been identified as a therapeutic target of rheumatoid arthritis (RA), while other metabolic regulators coordinating NAMPT to perpetuate inflammation are yet to ...
Lei M, Tao MQ, Wu YJ, Xu L, Yang Z, Li Y, Olatunji OJ, Wang XW, Zuo J.   +8 more
europepmc   +2 more sources

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review

Expert Opinion on Therapeutic Patents
Introduction Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD) from nicotinamide.
Massimiliano Gasparrini, Simone Giovannuzzi, Alessio Nocentini, Nadia Raffaelli, Claudiu T. Supuran   +4 more
openalex   +3 more sources

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process. [PDF]

Int J Mol Sci, 2021
Khaidizar FD, Bessho Y, Nakahata Y.
europepmc   +3 more sources

Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity. [PDF]

Cell Res, 2022
Yao H, Liu M, Wang L, Zu Y, Wu C, Li C, Zhang R, Lu H, Li F, Xi S, Chen S, Gu X, Liu T, Cai J, Wang S, Yang M, Xing GG, Xiong W, Hua L, Tang Y, Wang G.   +20 more
europepmc   +2 more sources

Nicotinamide phosphoribosyltransferase (NAMPT) [PDF]

Science-Business eXchange, 2012

  +6 more sources

Nicotinamide Phosphoribosyltransferase Inhibitors

, 2012
Nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12) catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate (PRPP) to yield nicotinamide mononucleotide (NMN), a rate limiting enzyme in a mammalian salvage pathway of nicotinamide adenine dinucleotide (NAD) synthesis.
Dan Wu, Dilyara Cheranova, Piotr Daniel, Li Qin, Shui Qing   +4 more
openalex   +4 more sources

Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and Toll-like receptor 4. [PDF]

J Biol Chem, 2022
Gasparrini M, Mazzola F, Cuccioloni M, Sorci L, Audrito V, Zamporlini F, Fortunato C, Amici A, Cianci M, Deaglio S, Angeletti M, Raffaelli N.   +11 more
europepmc   +2 more sources